Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, has been widely used as an
anti-platelet agent for the treatment of PAD. DP-R202 is a new Sarpogrelate hydrochloride
product improved patient's convenience and disadvantage of dosage regimen of previous drug.
The aim of this study was to compare the efficacy and safety of DP-R202 and Anplag® Tab in
patients with PAD